Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer
EOC-derived PDOs provide a robust platform for predicting chemotherapy response and offer added value in assessing PARPi efficacy beyond genomic profiling. Combination of organoid-based testing with genomic analysis may improve precision treatment strategies in EOC.
Authors
- Lin Zhong (ORCID: https://orcid.org/0000-0002-9224-9537)
- L. Wang
- Xueping Zhu
- Yuyu Lv
- Qinyue Jiang
- Haixia Wang (ORCID: https://orcid.org/0000-0002-4847-1421)
- Cong Zhang (ORCID: https://orcid.org/0000-0003-2443-2361)
- Xinghe Liu
- Misi He
- Qiaoling Li
- Dongling Zou
Institutions
- Chongqing University (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1186/s12967-025-07112-y
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 24.20